# PT-141 FAQ: Bremelanotide Questions Answered from the Record

> PT-141 questions answered from the cited record: what it is, how it works, the dosage as studied, how long it lasts, the side effects, and whether it is FDA-approved.

Direct answers on identity, mechanism, dosing, duration, and approval status — each cited where it makes a quantitative claim.

## Does PT-141 cause weight loss?

MC4R, the receptor PT-141 targets for desire, also sits in appetite circuits. Two Phase 1 trials in obese premenopausal women found high-frequency bremelanotide dosing lowered body weight (about 1.3 kg versus placebo over 16 days) and caloric intake (~400 kcal/day) [7]. This is an off-label research observation, not an approved use, and the dosing used was a short research protocol.

## What is PT-141?

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide that activates central melanocortin MC3R/MC4R receptors in the brain [1]. It is FDA-approved as a subcutaneous injection for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, and for no other indication [6].

## What is PT-141 peptide?

It is a seven-amino-acid cyclic peptide — an analogue of the natural hormone alpha-MSH — that works in the brain on melanocortin receptors rather than on blood vessels [1]. The cyclic ring structure makes it more stable than a linear peptide [6]. Its INN is bremelanotide and its molecular weight is 1025.2 Da [6].

## What does the PT-141 peptide do?

It activates MC4R (and MC3R) in hypothalamic and limbic circuits tied to sexual desire and arousal [1]. In the approved population, it modestly increased sexual desire and lowered desire-related distress in Phase 3 trials (integrated FSFI-desire +0.35, FSDS-DAO item-13 -0.33 versus placebo) [3].

## What is PT-141 used for?

Its single approved use is HSDD in premenopausal women [6]. All other uses — including in men, for erectile dysfunction, and in postmenopausal women — are off-label and supported only by early-phase or investigational data [1][13][14].

## Is PT-141 the same as bremelanotide?

Yes. Bremelanotide is the international nonproprietary name (INN) for the same molecule developed as PT-141 [6]. The approved injectable drug product is the finished pharmaceutical form; "PT-141 research chemical" is laboratory material, not the finished drug.

## What is bremelanotide?

Bremelanotide is the melanocortin receptor agonist approved in June 2019 (NDA 210557) as a 1.75 mg subcutaneous as-needed injection for HSDD in premenopausal women [6]. It is the INN for the molecule developed under the research designation PT-141 [1].

## How does PT-141 work?

It agonizes central melanocortin receptors (chiefly MC4R) in the hypothalamus and limbic system, engaging dopaminergic pathways of sexual motivation [1]. Unlike PDE-5 inhibitors, it acts on the brain's desire circuitry, not on vascular blood flow [1].

## What receptors does PT-141 act on?

Primarily the melanocortin 4 receptor (MC4R), with secondary activity at MC3R [1]. MC1R activation in skin underlies the hyperpigmentation seen with repeated frequent dosing [6].

## Does PT-141 work through the brain or through blood flow?

Through the brain. PT-141 acts centrally on melanocortin circuits of sexual motivation; it is mechanistically distinct from PDE-5 inhibitors, which act peripherally on vascular smooth muscle [1].

## What is a melanocortin receptor agonist?

A molecule that activates melanocortin receptors (MC1R-MC5R), the G-protein-coupled receptors for melanocortin peptides such as alpha-MSH [1]. PT-141 targets the central MC3R/MC4R subtypes.

## Does PT-141 increase testosterone?

No. PT-141 does not act via the HPG axis and does not directly raise testosterone; its effect on desire is mediated centrally through melanocortin signaling [1]. It is not a hormone therapy and not a PDE-5 inhibitor.

## How is PT-141 different from PDE-5 inhibitors?

PDE-5 inhibitors (such as sildenafil) work peripherally on penile blood flow; PT-141 works centrally on the neural circuitry of sexual desire and arousal [1]. The two act on entirely different targets, which is why a 2024 study is testing them in combination [14].

## What is the PT-141 dosage?

Reported as a finding only: the approved label specifies 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than eight per month [6]. This is the studied/label regimen, not a protocol to follow.

## How much PT-141 should I take?

The literature describes doses, not personal recommendations: 1.75 mg subcutaneous in the Phase 3 trials and label [3][6]; 0.75-1.75 mg in Phase 2 dose-finding [6]. We report what was studied and do not recommend a dose for any individual.

## How much PT-141 to inject?

In the trials and on the label the studied subcutaneous dose was 1.75 mg per as-needed use [3][6]. Early intranasal research in men used much higher milligram doses before that route was discontinued [1]. These are documented study figures, not instructions.

## What is the PT-141 dosage for women?

In premenopausal women with HSDD, the studied and approved dose is 1.75 mg subcutaneously, as needed (max one dose/24 h, eight/month) [6]. Reported as a label fact, not as guidance.

## How do you reconstitute PT-141?

The approved product is a prefilled autoinjector and does not require reconstitution [6]. Lyophilized "research chemical" PT-141 is a laboratory material, not the finished drug; this site does not provide preparation or self-administration instructions.

## How do you take PT-141?

The approved route is a subcutaneous injection into the abdomen or thigh, taken on an as-needed basis before anticipated activity [6]. Earlier development used an intranasal formulation that was discontinued for pharmacokinetic variability [1].

## How often can you take PT-141?

The label limits use to no more than one 1.75 mg dose per 24 hours and no more than eight doses per month [6]; tolerability (especially nausea) and the transient blood-pressure effect inform that ceiling [4][6].

## What is the approved bremelanotide dose?

1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity, capped at one dose per 24 hours and eight per month, per the US prescribing information [6].

## How long does PT-141 last?

The terminal half-life is about 2.7 hours (range 1.9-4.0 h) after subcutaneous dosing per the US label, with median Tmax near 0.5-1.0 hour [6]; in the functional-MRI study the desire effect was measurable for up to 24 hours [5].

---

A chrome-bright console reading of the bremelanotide record — the one approved indication, the modest effect, and the honest tolerability profile logged to source, with the community field reports quarantined apart; not a clinic, not a vendor, not a prescription.